Literature DB >> 8703856

Blood viscosity, coagulation, and activated protein C resistance in central retinal vein occlusion: a population controlled study.

T H Williamson1, A Rumley, G D Lowe.   

Abstract

BACKGROUND: The role of blood viscosity and haemostasis has been investigated in mixed groups of patients with branch and central retinal vein occlusion (CRVO) with conflicting results. This may have partly been due to the different aetiologies of these two types of vein occlusion.
METHODS: In this study viscosity and coagulation (including activated protein C resistance) were examined in 87 patients with CRVO and compared with the results from an age-matched, population based control group.
RESULTS: Viscosity variables were higher in CRVO than in controls which suggested that reduced red cell deformability was associated with the occurrence of CRVO. A higher percentage of the patients with CRVO (12%) had activated protein C resistance than controls (5%). Patients who developed the complication of iris neovascularisation had relatively low antithrombin III, factor VII, and tissue plasminogen activator indicating both a tendency to thrombus formation and a reduction in fibrinolytic activity.
CONCLUSION: Increased blood viscosity may contribute to the production of CRVO by inducing stasis of blood flow, with thrombus formation in at risk individuals who go on to develop iris neovascularisation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8703856      PMCID: PMC505429          DOI: 10.1136/bjo.80.3.203

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  36 in total

1.  Abnormal serum proteins and retinal vein thrombosis.

Authors:  H F SPALTER
Journal:  Arch Ophthalmol       Date:  1959-11

2.  Streptokinase in the treatment of central retinal vein occlusion. A controlled trial.

Authors:  E M Kohner; A M Hamilton; C J Bulpitt; C T Dollery
Journal:  Trans Ophthalmol Soc U K       Date:  1974-07

3.  Hyperviscosity syndrome with IgA myeloma.

Authors:  M E Dine; A T Guay; L M Snyder
Journal:  Am J Med Sci       Date:  1972-08       Impact factor: 2.378

4.  Hyperviscosity syndrome associated with immunoglobulin A myeloma.

Authors:  R J Freel; J E Maldonado; G J Gleich
Journal:  Am J Med Sci       Date:  1972-08       Impact factor: 2.378

5.  Retinopathy of Waldenström's macroglobulinemia: photographic assessment.

Authors:  E S Rosen; A V Simmons; T W Warnes
Journal:  Am J Ophthalmol       Date:  1968-05       Impact factor: 5.258

6.  Retinal circulation in the hyperviscosity syndrome.

Authors:  M N Luxenberg; F A Mausolf
Journal:  Am J Ophthalmol       Date:  1970-10       Impact factor: 5.258

7.  Hyperviscosity retinopathy. A scientific approach to therapy.

Authors:  C F Grindle; N A Buskard; D L Newman
Journal:  Trans Ophthalmol Soc U K       Date:  1976-07

8.  Systemic factors contributory to retinal vein occlusion.

Authors:  M A McGrath; F Wechsler; A B Hunyor; R Penny
Journal:  Arch Intern Med       Date:  1978-02

9.  Anticoagulant treatment of retinal venous occlusion.

Authors:  S Vannas; C Raitta
Journal:  Am J Ophthalmol       Date:  1966-11       Impact factor: 5.258

10.  Viscosity and retinal vein thrombosis.

Authors:  C P Ring; T C Pearson; M D Sanders; G Wetherley-Mein
Journal:  Br J Ophthalmol       Date:  1976-06       Impact factor: 4.638

View more
  25 in total

1.  Treatment of recent onset central retinal vein occlusion with intravitreal tissue plasminogen activator: a pilot study.

Authors:  A Glacet-Bernard; D Kuhn; A K Vine; H Oubraham; G Coscas; G Soubrane
Journal:  Br J Ophthalmol       Date:  2000-06       Impact factor: 4.638

Review 2.  Thrombophilia: genetic polymorphisms and their association with retinal vascular occlusive disease.

Authors:  M Chak; G R Wallace; E M Graham; M R Stanford
Journal:  Br J Ophthalmol       Date:  2001-07       Impact factor: 4.638

3.  Raised plasma homocysteine as a risk factor for retinal vascular occlusive disease.

Authors:  M Cahill; M Karabatzaki; R Meleady; H Refsum; P Ueland; D Shields; D Mooney; I Graham
Journal:  Br J Ophthalmol       Date:  2000-02       Impact factor: 4.638

Review 4.  Central retinal vein occlusion: what's the story?

Authors:  T H Williamson
Journal:  Br J Ophthalmol       Date:  1997-08       Impact factor: 4.638

5.  Activated protein C resistance in central retinal vein occlusion.

Authors:  G Sanborn
Journal:  Br J Ophthalmol       Date:  1996-12       Impact factor: 4.638

6.  Activated protein C resistance in patients with central retinal vein occlusion.

Authors:  J Larsson; A Sellman; B Bauer
Journal:  Br J Ophthalmol       Date:  1997-10       Impact factor: 4.638

7.  Therapeutic potential of intravitreal pharmacotherapy in retinal vein occlusion.

Authors:  Marianne L Shahsuvaryan
Journal:  Int J Ophthalmol       Date:  2012-12-18       Impact factor: 1.779

8.  Hemorheological disorders in diabetes mellitus.

Authors:  Young I Cho; Michael P Mooney; Daniel J Cho
Journal:  J Diabetes Sci Technol       Date:  2008-11

9.  Cardiovascular risk factors and outcome in patients with retinal vein occlusion.

Authors:  Mirko Di Capua; Antonio Coppola; Rosina Albisinni; Antonella Tufano; Anna Guida; Matteo Nicola Dario Di Minno; Ferdinando Cirillo; Marcello Loffredo; Anna Maria Cerbone
Journal:  J Thromb Thrombolysis       Date:  2010-07       Impact factor: 2.300

10.  [Retinal vein branch occlusion and palsy of the N. abducens in protein S deficiency].

Authors:  H M Holak; N H Holak; S Holak; S A Holak; S Szymaniec
Journal:  Ophthalmologe       Date:  2005-03       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.